Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc > i think now CEO is considering to sell the company

<< Previous

Bullboard Posts

Next >>

Comment by PitchinPennieson Jan 15, 2021 11:09pm

221 Views

Post# 32312431

RE:RE:RE:RE:i think now CEO is considering to sell the company

Don't blame yourself, Michel. It might have worked out, except that the controlling family and their three or four acolytes never cared about investors and never spent a minute of time in the real world. A buck-fifty might have been a possible exit price before Junior burnt the house down. Now things have changed. Innovotech will accumulate in a 70-80 cent range. There are no other serious acquirers on the horizon. Nosepick and Southern Tier Tom, feel free to sound off.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec